Caner Saygin
University of Chicago
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Caner Saygin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:17 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07294677 · CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBLUniversity of Chicago · recruiting · Leukemia, Lymphoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Role of SASH3 in normal and malignant T cellsR37CA309658 · NCI · UNIVERSITY OF CHICAGO · fiscal years 2026 · $450,685 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:17 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.Blood Cancer J · 201843 citationsRCR 1.3
- Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.Haematologica · 202514 citationsRCR 3.2
- 4 citationsRCR 0.2